CN101200443B - Nitrogen heterocyclic methyl ethyl ketone derivatives, preparation method and medicine combination containing the same - Google Patents
Nitrogen heterocyclic methyl ethyl ketone derivatives, preparation method and medicine combination containing the same Download PDFInfo
- Publication number
- CN101200443B CN101200443B CN200710133305XA CN200710133305A CN101200443B CN 101200443 B CN101200443 B CN 101200443B CN 200710133305X A CN200710133305X A CN 200710133305XA CN 200710133305 A CN200710133305 A CN 200710133305A CN 101200443 B CN101200443 B CN 101200443B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- azetidinone
- hydroxypropyl
- instead
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JCAZSWWHFJVFPP-UHFFFAOYSA-N COC(CCCC(Cl)=O)=O Chemical compound COC(CCCC(Cl)=O)=O JCAZSWWHFJVFPP-UHFFFAOYSA-N 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N O=C(CCC1)OC1=O Chemical compound O=C(CCC1)OC1=O VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the substituted azetidinone as the medicine for reducing the plasma cholesterol which is used in the treatment and the prevention of the atherosclerosis. The synthetic method comprises their drug combination, wherein, the definition of R1, Ar1 and Ar2 refers to the specification.
Description
Technical field
The present invention relates to be used as in atherosis at treatment and prevention of arterial the substituted azetidinone of reduction plasma cholesterol medicine, their synthetic method contains their drug regimen.
Background technology
By the hyperlipidaemia due to the abnormalities of sugar/lipid metabolism one of Hazard Factor that cause atherosclerosis and other cardiovascular and cerebrovascular diseases.The clinical treatment medicine of hyperlipidaemia mainly contains statins, fibrate and nicotinic acid derivates, but these Side effects of pharmaceutical drugs are also clearly.Particularly the Cerivastatin in the statins is because the side effect of rhabdomyolysis causes many cases clinically dead case.(3R, 4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone (ezetimibe, Ezetimibe, Zetia
TM) be the novel cholesterol absorption inhibitor of Merck/Schering-Plough company development, to go on the market in Germany in November, 2002, go on the market in the U.S. same period.This medicine can reach the purpose that reduces cholesterol in the blood plasma by the absorption that optionally suppresses small intestine place cholesterol, the effect of performance reducing blood-fat.Only ezetimibe listing in the cholesterol absorption inhibitor at present, but and ezetimibe reflectivity ground cause the increase of liver synthesis cholesterol, thereby slacken the effect that it falls plasma cholesterol.Therefore it is strong to seek cholesterol-lowering activity, and the low cholesterol absorption inhibitor of side effect becomes the technological difficulties of this research direction most critical.
Summary of the invention
The object of the present invention is to provide the novel cholesterol absorption inhibitor of a class, it is stronger that it falls the plasma cholesterol activity, and security is higher.
The present invention also aims to provide a kind of preparation method of synthesizing new cholesterol absorption inhibitor.
Another object of the present invention also is to provide a kind of pharmaceutical preparation that contains cholesterol absorption inhibitor.
Summary of the invention is as follows in detail:
The present invention has synthesized a series of general formulas (I) compound:
Wherein:
Ar
1Represent R
2The aryl of-replacement; Ar
2Represent R
3The aryl of-replacement;
R
1Represent R
4The aryl of-replacement or benzyl, low alkyl group;
R
2-, R
3-and R
4-represent 1-5 substituting group, they independently are selected from and comprise :-OR
5,-O (CO) R
5,-O (CO) OR
5,-O (CH
2)
1-5OR
5,-O (CH
2)
1-2O-,-O (CO) NR
5R
6,-NR
5R
6,-NR
5(CO) R
6,-NR
5(CO) OR
6,-NR
5(CO) NR
6R
7,-NR
5SO
2-low alkyl group ,-NR
5SO
2-aryl ,-CONR
5R
6,-COR
5,-SO
2NR
5R
6, S (O)
0-2-alkyl, S (O)
0-2-aryl ,-O (CH
2)
1-10-COOR
5,-O (CH
2)
1-10CONR
5R
6, hydrogen, neighbour-halo ,-halo, right-halo, neighbour-low alkyl group ,-low alkyl group, right-low alkyl group, aryl ,-NO
2, CF
3,-(low-grade alkylidene)-COOR
5With-CH=CH-COOR
5
R
5, R
6And R
7Independently be selected from: hydrogen, low alkyl group, aryl, the low alkyl group that aryl replaces.
Preferred compound is:
Instead-1-(4-chloro-phenyl-)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I1);
Instead-1-(4-chloro-phenyl-)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I2);
Instead-1-(4-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I3);
Instead-1-(4-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I4);
Instead-1-phenyl-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I5);
Instead-1-(4-p-methoxy-phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I6);
Instead-1-phenyl-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I7);
Instead-1-(2-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I8);
Instead-1-(2-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I9);
Instead-1-(4-fluorophenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I10);
Instead-and 1-(2-aminomethyl phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation (I11) of 4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-and 1-(4-p-methoxy-phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation (I12) of 4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-chloro-phenyl-)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation (I13) of 4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-aminomethyl phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation (I14) of 4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-and 1-(4-fluorophenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation (I15) of 4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-ethoxyl phenenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation (I16) of 4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-bromophenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation (I17) of 4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-chloro-phenyl-)-3-[3,3-dibenzyl-3-hydroxypropyl]-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I18);
Instead-and 1-(4-p-methoxy-phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(3,4-dioxy methylene radical-6-bromophenyl)-2-azetidinone (I19).
The structural formula that it is corresponding:
R
1 Ar
1 Ar
2
I1 -Ph?
I2 -Ph?
I3 -Ph?
I4 -Ph?
I5 -Ph?
I6 -Ph?
I7 -Ph?
I8 -Ph?
I9 -Ph?
I10 -Ph?
I11?
I12?
I13?
I14?
I15?
I16?
I17?
I18?
I19?
General formula (I) compounds process for production thereof is as follows: substituted aroma aldehyde and substituted aromatic amine reaction, generate intermediate (II), carry out the Staudinger cycloaddition with the chloroformyl methyl-butyrate again, generate intermediate (III), last and corresponding Grignard reagent reaction obtains target compound (I).Route is as follows:
Wherein the preparation of key intermediate chloroformyl methyl-butyrate is by the Pyroglutaric acid alcoholysis, and chloride obtains again.Concrete reaction scheme is as follows:
Below be the pharmacological experiment data of invention part of compounds:
1, animal, reagent and instrument
1.1 animal
Male SD rat, 180-220g, the The 2nd Army Medical College Experimental Animal Center provides, and credit number is: SCXK (Shanghai) 2002-0006
1.2 reagent
Cholesterol provides for the emerging chemical reagent in Shanghai institute, and lot number is 020628
Total cholesterol (TC) is measured test kit and is provided for Shanghai Rongsheng Bioisystech Co., Ltd, and lot number is that 20070205 high-density lipoprotein (HDL) (HDL) mensuration test kit provides for Tianjin, Wenzhou agate bio tech ltd, and lot number is: 2007040213
1.3 the preparation of test-compound and positive drug
Test-compound and positive drug faced with preceding the grinding with 0.05%CMC-Na solution be mixed with suspension.
1.4 instrument
T6 new millennium ultraviolet-visible pectrophotometer: Beijing Puxi General Instrument Co., Ltd
2, method
Healthy male SD rat is divided into blank group, model group, positive drug group and is subjected to the reagent group, 8 every group; Each treated animal is irritated stomach to high-fat emulsion once equal every day, each 2ml, and gastric infusion again after two hours, continuous 7 days, got blood and put to death half an hour after administration the last day, measures plasma total cholesterol levels and hdl concentration.
The preparation of high-fat emulsion: get lard 25g, be placed in the 200ml beaker, magnetic agitation is heated to 100 ℃, adds the 10g cholesterol, dissolves, and it is excellent to add 1g third match again, fully stirs evenly, and adds the 25ml tween 80, makes oil phase; Get another beaker and add 30ml distilled water and 1,2-propylene glycol 20ml is placed on and is heated to 60 ℃ on the electric furnace, adds the 2g Sodium desoxycholate then, fully stirs up to dissolving fully, makes water; Water is added oil phase, abundant mixing, high-fat emulsion.
3, experimental result
Table 1, compound are to the inhibition activity of rat cholesterol absorption
(?
n＝8)
| Sequence number | Test-compound | Dosage (mg/kg) | TC content (mmol/L) | HDL content (mmol/L) |
| 1 2 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 | Blank group model group ezetimibe I 1 I 2 I 3 I 4 I 5 I 6 I 7 I 8 I 9 I 10 I 11 I 12 I 13 I 14 I 15 | 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 | 10.73±0.99 13.26±1.59 11.01±1.27 11.00±1.32 11.67±0.94 12.35±0.91 10.64±0.55 11.66±1.11 12.70±1.96 13.44±1.92 11.78±1.86 13.13±1.60 13.27±0.80 13.21±0.60 11.94±2.20 13.24±1.24 13.27±1.17 13.16±0.30 | 4.00±0.47 2.80±0.15 3.44±0.52 2.99±0.26 2.94±0.37 2.92±0.35 3.26±0.41 3.02±0.56 3.49±0.14 3.26±0.13 2.95±0.32 3.46±0.33 3.77±0.54 3.40±0.29 3.06±0.44 3.10±0.19 2.91±0.37 3.04±0.21 |
[0078]?
| 20 21 22 23 | I 16 I 17 I 18 I 19 | 50 50 50 50 | 11.12±1.81 13.21±1.06 13.24±0.69 13.31±0.40 | 2.40±0.29 3.61±0.39 3.31±0.39 3.59±0.16 |
Above pharmacology data shows, the reduction plasma cholesterol effect that general formula of the present invention (I) compound tool is stronger.
The present invention also comprises pharmaceutical preparation, and said preparation comprises general formula (I) compound and the pharmaceutically acceptable carrier as promoting agent.Pharmaceutically acceptable carrier is meant one or more inert, atoxic solid or liquid filler material, thinner, auxiliary agent etc., and their not reverse and active compounds or patient have an effect.
But common formulations on the pharmaceuticies such as the formulation tablet of the present composition, capsule, pill, suppository, soft capsule, oral liquid, suspensoid, injection liquid.
Tablet for oral use and capsule contain traditional vehicle such as weighting material, thinner, lubricant, dispersion agent and tackiness agent.Can be prepared according to the method for knowing in this area.
The dosage of above active compound will be different because of prescription.
Usually, prove favourable amount for reaching required result, the total amount of per 24 hours administration general formulas (I) of every kg body weight compound is about 0.01-100mg, the preferred about 0.1-50mg of total amount.If necessary, with the form administration of single dose several times.Yet, if necessary, also can depart from above-mentioned consumption, promptly this depends on experimenter's to be treated type and body weight, individual behavior to medicine, the character of disease and type and the administration time or the interval of seriousness, preparation and administration.
By the following examples the present invention is done into description.
Embodiment:
Embodiment 1
The preparation of chloroformyl methyl-butyrate
50g (0.439mol) Pyroglutaric acid is dissolved in the 30ml anhydrous methanol, and behind the reflux 1h, unreacted methanol is removed in underpressure distillation; Reaction solution is cooled to room temperature, slowly adds 100ml thionyl chloride and 3 DMF, behind the reflux 2h, the water pump underpressure distillation, remove remaining thionyl chloride after, use the oil pump underpressure distillation again, collect the cut of 96-98 ℃/10mmHg, get weak yellow liquid 62.1g, yield: 86.1%.
Embodiment 2
The preparation of N-(3,4-dioxy methylene-benzene methylene radical)-4-monomethylaniline (II4)
Add the 7.5g piperonylaldehyde in 500ml two neck bottles, 5.36g is to monomethylaniline, the catalytic amount tosic acid, and 250ml toluene, oil bath is heated to backflow, induction stirring, fraction water device water-dividing reacted 12 hours, and TLC follows the tracks of reaction process.Reaction is finished, suction filtration while hot, filter cake discards, filtrate be spin-dried for crude product 10.9g, yield: 85.0%.
Embodiment 3
Instead-and 3-[2-oxo-4-(3,4-dioxy methylene radical phenyl)-1-(4-aminomethyl phenyl)-2-azelidinyl] preparation of methyl propionate (III4)
Add 9.2g (0.038mol) N-(3 in the 250ml three-necked flask, 4-dioxy methylene radical phenyl)-the 4-monomethylaniline, 130ml toluene, 27.4ml (0.114mol) tri-n-butylamine, after the reflux, slowly splash into the solution of 12.7g (0.076mol) chloroformyl methyl-butyrate and 10ml toluene, reaction solution is the faint yellow redness that becomes rapidly, and the dropping process needs 0.5h approximately, continues reflux 8h, cooling, add the rare HCl 40ml of 1mol/L, behind the stirring at room 15min, with EtOAc extraction (50ml*3), organic phase is used the rare HCl of 1mol/L (50ml*3), saturated NaHCO successively
3(50ml*3), saturated aqueous common salt (50ml*3) is washed, and anhydrous sodium sulfate drying filters, concentrate, and system sand, column chromatography purification gets white needle-like crystals 9.2g, productive rate: 65.1%.
Embodiment 4
Instead-preparation of 1-(4-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I4)
In the 100ml three-necked bottle, add 1.3g (III4), it is dissolved in 50 anhydrous diethyl ethers then, slowly be added drop-wise among the 7.5mmol Grignard reagent PhMgBr, keep refluxing, have a large amount of white solids to generate.Drip and finish the 40min that refluxes again, stopped reaction, remove oil bath, add ice-water bath, in reaction flask, pour the mixture termination reaction of 1mol/LHCl and trash ice then into, extracted with diethyl ether, washing, drying, concentrate faint yellow oily thing 1.1g, with the THF dissolving, add the capacity LiOH aqueous solution, stirring at room 6h, use ethyl acetate extraction, saturated NaCl washes twice, anhydrous MgSO
4Drying is filtered, and filtrate concentrates, column chromatography for separation (ethyl acetate: sherwood oil=1: 5), get white solid 0.60g, yield: 34.5%; Mp:169-170 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.90(2H，m，-CH
2-)，2.26(3H，s，Ar-CH
3)，2.42(2H，m，-CH
2-)，3.15(1H，d，-CH-)，4.46(1H，d，-NCH-)，5.95(2H，d，-OCH
2O-)，6.77~7.29(17H，m，Ar-H)；
MS(ESI+，m/z)：514.3[M+Na
+]。
Embodiment 5
Instead-preparation of 1-(4-chloro-phenyl-)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I1)
With reference to the preparation method of I4, be starting raw material with aubepine and p-Chlorobenzoic acid amide, get white solid 0.58g, yield: 35.2%; Mp:64-67 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.64(1H，m，-OH)，1.93(2H，m，-CH
2-)，2.42(2H，m，-CH
2-)，3.15(1H，d，-CH-)，3.80(3H，s，-OCH
3)，4.51(1H，d，-NCH-)，6.88~7.42(18H，m，Ar-H)；MS(ESI+，m/z)：520.2[M+Na
+]。
Embodiment 6
Instead-preparation of 1-(4-chloro-phenyl-)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I2)
With reference to the preparation method of I4, with 3,4-dioxy methylene-benzene formaldehyde and p-Chlorobenzoic acid amide are starting raw material, get white solid 0.71g, yield: 33.7%; Mp:147-150 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.90(2H，m，-CH
2-)，2.45(2H，m，-CH
2-)，3.10(1H，d，-CH-)，4.46(1H，d，-NCH-)，5.97(2H，d，-OCH
2O-)，6.75~7.42(17H，m，Ar-H)；
MS(ESI+，m/z)：534.3([M+Na
+])。
Embodiment 7
Instead-preparation of 1-(4-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I3)
With reference to the preparation method of I4, be starting raw material with aubepine with to monomethylaniline, get pure product 0.65g, yield: 39.2%; Mp:130-131 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.64(1H，m，-OH)，1.86(2H，m，-CH
2-)，2.25(3H，s，-ArCh
3)，2.42(2H，m，-CH
2-)，2.48(1H，s，-OH)，3.05(1H，d，-CH-)，3.80(3H，s，-OCH
3)，4.51(1H，d，-NCH-)，6.87~7.42(18H，m，Ar-H)；
MS(ESI+，m/z)：500.3([M+Na
+])。
Embodiment 8
Instead-preparation of 1-phenyl-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I5)
With reference to the preparation method of I4, be starting raw material with aubepine and aniline, get pure product 0.80g, yield: 37.4%; Mp:128-131 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.64(1H，m，-OH)，1.85(2H，m，-CH
2-)，2.44(2H，m，-CH
2-)，3.09(1H，d，-CH-)，3.80(3H，s，-OCH
3)，4.53(1H，d，-NCH-)，6.88~7.43(19H，m，Ar-H)；
MS(ESI+，m/z)：486.3([M+Na
+])。
Embodiment 9
Instead-preparation of 1-(4-p-methoxy-phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I6)
With reference to the preparation method of I4, with 3,4-dioxy methylene-benzene formaldehyde and P-nethoxyaniline are starting raw material, get pure product 0.67g, yield: 36.7%; Mp:154-156 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.88(2H，m，-CH
2-)，2.42(2H，m，-CH
2-)，3.09(1H，d，-CH-)，3.74(3H，s，-OCH
3)，4.45(1H，d，-NCH-)，5.95(2H，d，-OCH
2O-)，6.76~7.43(17H，m，Ar-H)；
MS(ESI+，m/z)：530.1([M+Na
+])。
Embodiment 10
Instead-preparation of 1-phenyl-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I7)
With reference to the preparation method of I4, with 3,4-dioxy methylene-benzene formaldehyde and aniline are starting raw material, must get pure product 0.55g, yield: 34.7%; Mp:132-135 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.88(2H，m，-CH
2-)，2.42(2H，m，-CH
2-)，3.08(1H，d，-CH-)，4.48(1H，d，-NCH-)，5.95(2H，d，-OCH
2O-)，6.79~7.43(17H，m，Ar-H)；
MS(ESI+，m/z)：500.1([M+Na
+])。
Embodiment 11
Instead-preparation of 1-(2-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I8)
With reference to the preparation method of I4, be starting raw material with aubepine and Ortho Toluidine, get pure product 0.60g, yield: 35.0%;
1H-NMR(CDCl
3，300Hz)δ：1.94(2H，m，-CH
2-)，2.36(3H，s，-ArCH
3)，2.47(2H，m，-CH
2-)，3.18(1H，d，-CH-)，4.68(1H，d，-NCH-)，3.76(3H，s，-OCH
3)，6.83~7.96(18H，m，Ar-H)；
MS(ESI+，m/z)：500.2([M+Na
+])。
Embodiment 12
Instead-preparation of 1-(2-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I9)
With reference to the preparation method of I4, with 3,4-dioxy methylene-benzene formaldehyde and Ortho Toluidine are starting raw material, get pure product 0.73g, yield: 36.4%.
1H-NMR(CDCl
3，300Hz)δ：1.90(2H，m，-CH
2-)，2.37(3H，s，-ArCH
3)，2.43(2H，m，-CH
2-)，3.13(1H，d，-CH-)，4.65(1H，d，-NCH-)，5.93(2H，d，-OCH
2O-)，6.74~7.45(17H，m，Ar-H)；
MS(ESI+，m/z)：514.1([M+Na
+])。
Embodiment 13
Instead-preparation of 1-(4-fluorophenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone (I10)
With reference to the preparation method of I4, be starting raw material with aubepine and para-fluoroaniline, get pure product 0.84g, yield: 36.4%.
1H-NMR(CDCl
3，300Hz)δ：1.89(2H，m，-CH
2-)，2.43(2H，m，-CH
2-)，3.07(1H，d，-CH-)，3.80(3H，s，-OCH
3)，4.50(1H，d，-NCH-)，6.88~7.43(18H，m，Ar-H)
MS(ESI+，m/z)：504.1([M+Na
+])。
Embodiment 14
Instead-and 1-(2-aminomethyl phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation of the preparation (I11) of 4-(3,4-dioxy methylene radical phenyl)-2-azetidinone
With reference to the preparation method of I4, with 3,4-dioxy methylene-benzene formaldehyde and Ortho Toluidine are starting raw material, white solid 0.8g, productive rate: 21.4%, mp:89.0～91.0 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.90(2H，m，-CH
2-)，2.37(3H，s，Ar-CH
3)，2.41(1H，m，-OH)，2.72(2H，m，-CH
2-)，3.15(1H，d，-CH-)，4.64(1H，d，-NCH-)，5.93(2H，m，-OCH
2O-)，6.74~7.40(15H，m，Ar-H)；
MS(ESI+，m/z)：[M+Na]
+550.2。
Embodiment 15
Instead-and 1-(4-p-methoxy-phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation of the preparation (I12) of 4-(4-p-methoxy-phenyl)-2-azetidinone
With reference to the preparation method of I4, be starting raw material with aubepine and P-nethoxyaniline, get white solid 0.9g, productive rate: 24.6%; Mp:130.0～131.0 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.85(2H，m，-CH
2-)，2.37(1H，m，-OH)，2.63(2H，m，-CH
2-)，3.08(1H，d，-CH-)，3.73(3H，s，-OCH
3)，3.80(3H，s，-OCH
3)，4.48(1H，d，-NCH-)，6.75~7.38(16H，m，Ar-H)；
MS(ESI+，m/z)：[M+Na]
+552.2。
Embodiment 16
Instead-and 1-(4-chloro-phenyl-)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation of the preparation (I13) of 4-(4-p-methoxy-phenyl)-2-azetidinone
With reference to the preparation method of I4, be starting raw material with aubepine and p-Chlorobenzoic acid amide, white solid 1.1g, productive rate: 26.0%, mp:91.0～93.0 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.86(2H，m，-CH
2-)，2.40(1H，m，-OH)，2.48(2H，m，-CH
2-)，3.10(1H，d，-CH-)，3.81(3H，s，-OCH
3)，4.50(1H，d，-NCH-)，6.88~7.38(16H，m，Ar-H)；MS(ESI+，m/z)：[M+Na]
+556.2。
Embodiment 17
Instead-and 1-(4-aminomethyl phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation of the preparation (I14) of 4-(3,4-dioxy methylene radical phenyl)-2-azetidinone
With reference to the preparation method of I4, with 3,4-dioxy methylene-benzene formaldehyde and para-totuidine are starting raw material, white solid 1.9g, productive rate: 31.5%, mp:121.0～123.0 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.86(2H，m，-CH
2-)，2.26(3H，s，Ar-CH
3)，2.37(1H，m，-OH)，2.54(2H，m，-CH
2-)，3.06(1H，d，-CH-)，4.45(1H，d，-NCH-)，5.95(2H，m，-OCH
2O-)，6.77~7.38(15H，m，Ar-H)；
MS(ESI+，m/z)：[M+Na]
+550.2。
Embodiment 18
Instead-and 1-(4-fluorophenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation of the preparation (I15) of 4-(4-p-methoxy-phenyl)-2-azetidinone
With reference to the preparation method of I4, be starting raw material with aubepine and para-fluoroaniline, white solid 1.9g, productive rate: 29.2%, mp:100.0～103.0 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.88(2H，m，-CH
2-)，2.38(1H，m，-OH)，2.50(2H，m，-CH
2-)，3.10(1H，d，-CH-)，3.81(3H，s，-OCH
3)，4.50(1H，d，-NCH-)，6.89~7.38(16H，m，Ar-H)；
MS(ESI+，m/z)：[M+Na]
+540.3。
Embodiment 9
Instead-and 1-(4-ethoxyl phenenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation of the preparation (I16) of 4-(4-p-methoxy-phenyl)-2-azetidinone
With reference to the preparation method of I4, be starting raw material with aubepine and p-ethoxyaniline, white solid 1.3g, productive rate: 30.0%, mp:137.0～139.0 ℃.
1H-NMR(CDCl
3，300Hz)δ：1.36(3H，m，-CH
3)，1.85(2H，m，-CH
2-)，2.38(1H，m，-OH)，2.56(2H，m，-CH
2-)，3.08(1H，d，-CH-)，3.80(3H，s，-CH
3)，3.93(2H，m，-CH
2-)，4.48(1H，d，-NCH-)，6.74~7.39(16H，m，Ar-H)；
MS(ESI+，m/z)：[M+Na]
+566.3。
Embodiment 20
Instead-and 1-(4-bromophenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation of the preparation (I17) of 4-(4-p-methoxy-phenyl)-2-azetidinone
With reference to the preparation method of I4, be starting raw material with aubepine and para-bromoaniline, get white solid 1.1g, productive rate: 19.9%; Mp:122.0～124.0 ℃,
1H-NMR (CDCl
3, 300Hz) δ: 1.86 (2H, m ,-CH
2-), 2.30 (1H, m ,-OH), 2.47 (2H, m ,-CH
2-), 3.10 (1H, m ,-CH-), 3.81 (3H, s ,-OCH
3), 4.50 (1H, d ,-NCH-), 6.88 ~ 7.38 (16H, m, Ar-H);
MS(ESI+，m/z)：[M+Na]
+601.0
Embodiment 21
Instead-and 1-(4-chloro-phenyl-)-3-[3,3-dibenzyl-3-hydroxypropyl]-preparation of 4-(3,4-dioxy methylene radical phenyl)-2-azetidinone (I18)
With reference to the preparation method of I4, with 3,4-dioxy methylene-benzene formaldehyde and p-Chlorobenzoic acid amide are starting raw material, get faint yellow solid 0.7g, productive rate: 19.5%;
1H-NMR(CDCl
3，300Hz)δ：1.57(2H，m，-CH
2-)，1.97(2H，m，-CH
2-)，2.75(2H，s，PhCH
2-)，?2.80(2H，d，PhCH
2-)，2.97(1H，d，-CH-)，4.26(1H，d，-NCH-)，5.92(2H，m，-OCH
2O-)，6.52~7.35(17H，m，Ar-H)；
MS(ESI+，m/z)：[M+Na]
+562.3
Embodiment 22
Instead-and 1-(4-p-methoxy-phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-preparation of 4-(3,4-dioxy methylene radical-6-bromophenyl)-2-azetidinone (I19)
With reference to the preparation method of I4, with 3,4-dioxy methylene radical-6-bromobenzaldehyde and P-nethoxyaniline are starting raw material, get faint yellow solid 0.6g, productive rate: 21.5%;
1H-NMR(CDCl
3，300Hz)δ：1.93(2H，m，-CH
2-)，2.47(2H，m，-CH
2-)，3.02(1H，d，-CH-)，3.76(3H，s，-OCH
3)，5.00(1H，d，-NCH-)，5.95(2H，m，-OCH
2O-)，6.68~7.49(14H，m，Ar-H)；
MS(ESI+，m/z)：[M+Na]
+644.2。
Embodiment 23
The tablet that contains promoting agent I4:
Every contains (mg)
I4 50mg
Lactose 100mg
W-Gum 40mg
Magnesium Stearate 1.5mg
Ethanol is an amount of
According to a conventional method supplementary material is mixed, granulate drying, compressing tablet.
Claims (3)
1. following arbitrary compound and pharmacologically acceptable salt thereof:
Instead-1-(4-chloro-phenyl-)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-1-(4-chloro-phenyl-)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-1-(4-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-1-(4-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-1-phenyl-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-1-(4-p-methoxy-phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-1-phenyl-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-1-(2-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-1-(2-aminomethyl phenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-1-(4-fluorophenyl)-3-(3,3-phenylbenzene-3-hydroxypropyl)-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(2-aminomethyl phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-and 1-(4-p-methoxy-phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-chloro-phenyl-)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-aminomethyl phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-and 1-(4-fluorophenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-ethoxyl phenenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-bromophenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(4-p-methoxy-phenyl)-2-azetidinone;
Instead-and 1-(4-chloro-phenyl-)-3-[3,3-dibenzyl-3-hydroxypropyl]-4-(3,4-dioxy methylene radical phenyl)-2-azetidinone;
Instead-and 1-(4-p-methoxy-phenyl)-3-[3,3-two (4-fluorophenyl)-3-hydroxypropyl]-4-(3,4-dioxy methylene radical-6-bromophenyl)-2-azetidinone.
2. each described compound or pharmaceutically acceptable salt thereof is used to prepare treatment or prevention of arterial is atherosis or reduce the purposes of the medicine of blood plasma cholesterol level in the claim 1.
3. a pharmaceutical composition wherein contains each the described compound or pharmaceutically acceptable salt thereof of claim 1 and the pharmaceutically acceptable carrier for the treatment of significant quantity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710133305XA CN101200443B (en) | 2007-10-17 | 2007-10-17 | Nitrogen heterocyclic methyl ethyl ketone derivatives, preparation method and medicine combination containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710133305XA CN101200443B (en) | 2007-10-17 | 2007-10-17 | Nitrogen heterocyclic methyl ethyl ketone derivatives, preparation method and medicine combination containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101200443A CN101200443A (en) | 2008-06-18 |
| CN101200443B true CN101200443B (en) | 2011-06-29 |
Family
ID=39515839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710133305XA Expired - Fee Related CN101200443B (en) | 2007-10-17 | 2007-10-17 | Nitrogen heterocyclic methyl ethyl ketone derivatives, preparation method and medicine combination containing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101200443B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102775366A (en) * | 2011-05-10 | 2012-11-14 | 上海医药工业研究院 | Preparation method for 3-(5-methoxy-1,5-dioxopenyl)-(4S)-phenyloxazolidin-2-one |
| CN104447489B (en) * | 2014-12-29 | 2017-01-11 | 南京工业大学 | 3, 4-diaryl maleimide derivative and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1144522A (en) * | 1994-03-25 | 1997-03-05 | 先灵公司 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US20040082561A1 (en) * | 2002-06-19 | 2004-04-29 | Gerhard Jaehne | Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| CN1662495A (en) * | 2002-06-19 | 2005-08-31 | 安万特医药德国有限公司 | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| WO2006116499A1 (en) * | 2005-04-26 | 2006-11-02 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
| CN1898203A (en) * | 2003-12-23 | 2007-01-17 | 阿斯利康(瑞典)有限公司 | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
-
2007
- 2007-10-17 CN CN200710133305XA patent/CN101200443B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1144522A (en) * | 1994-03-25 | 1997-03-05 | 先灵公司 | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US20040082561A1 (en) * | 2002-06-19 | 2004-04-29 | Gerhard Jaehne | Ring -substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| CN1662495A (en) * | 2002-06-19 | 2005-08-31 | 安万特医药德国有限公司 | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| CN1898203A (en) * | 2003-12-23 | 2007-01-17 | 阿斯利康(瑞典)有限公司 | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
| WO2006116499A1 (en) * | 2005-04-26 | 2006-11-02 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101200443A (en) | 2008-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5656624A (en) | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents | |
| TW199144B (en) | ||
| EP1682503B1 (en) | Derivatives of n-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| CN101684118B (en) | Use of tricyclic compounds as glycine transport inhibitors | |
| CN101918376B (en) | 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors | |
| SK61697A3 (en) | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents | |
| WO1998029409A1 (en) | Acid-addition salts of optically active piperidine compound and process for producing the same | |
| JP2022502510A (en) | Nitroxoline prodrug and its use | |
| TW200413311A (en) | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | |
| US20230286904A1 (en) | Inhibitors of yap/taz-tead oncoproteins, synthesis and use thereof | |
| WO2014127722A1 (en) | Dihydroartemisinin substituted by nitrogen containing heterocycle derivative and use thereof | |
| CN101200443B (en) | Nitrogen heterocyclic methyl ethyl ketone derivatives, preparation method and medicine combination containing the same | |
| JP4444375B2 (en) | Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain | |
| CN103360342B (en) | 3-cyano-aniline alkylaryl bridged piperazine derivatives and preparing the application in medicine | |
| CN104447489B (en) | 3, 4-diaryl maleimide derivative and preparation method and application thereof | |
| CA2709863A1 (en) | Azetidine derivatives, their preparation and their application in therapy | |
| CN108349872A (en) | The synthesis of terphenyl compounds | |
| EP4198017A1 (en) | Benzylamine derivative, preparation method therefor and use thereof | |
| JPH02229168A (en) | Pyrazolone derivative | |
| PT1032559E (en) | Aminoalkylphenol derivatives for treating depression and memory dysfunction | |
| EP4227293A2 (en) | Crystalline forms of 1-(acyloxy)-alkyl carbamate drug conjugates of naproxen and pregabalin | |
| CN101759665B (en) | Substituent phenylpiperazine aryl alkanol derivant and application thereof in preparing analgesics | |
| FR2670780A1 (en) | 4-(Acylamino)benzopyran derivatives, their preparation and their application in therapeutics | |
| WO2008157271A1 (en) | Deuterium-enriched escitalopram | |
| JP2022546958A (en) | MAGL inhibitors and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110629 Termination date: 20211017 |